Valuation
Is the price right?3/3 inputs reported · High confidence
Weaker than most peers on:
- ▼ Earnings yield
- ▼ EBITDA yield
Behind the score
Sector-normalized EBITDA, earnings, and free cash flow yields.
Bringing the fundamentals into focus…
Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026
3/3 inputs reported · High confidence
Weaker than most peers on:
Sector-normalized EBITDA, earnings, and free cash flow yields.
Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.
3/3 inputs reported · High confidence
Weaker than most peers on:
Return on invested capital, operating margin, and return on assets.
2/3 inputs reported · Partial data
Stronger than most peers on:
Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Got weaker
Worth watching: Alumis is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.
| Previous quarter | Latest quarter | Change | |
|---|---|---|---|
| Revenue (12 months) | 8.4M USD | 7.4M USD | −11.9% |
| Net income (12 months) | −237.4M USD | −439.0M USD | +84.9% |
| Operating margin | -5364.0% | -6204.4% | −840.4 pts |
| Free cash flow (12 months) | −377.0M USD | −351.8M USD | −6.7% |
| Cash | 63.9M USD | 63.7M USD | −0.3% |
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Valuations in Biotechnology are within their usual range since 2016.
Earnings-based measures are left out for now because many companies in Biotechnology are losing money.
| Key ratios | FY 2023 | FY 2024 | FY 2025 | Change |
|---|---|---|---|---|
| Operating margin | — | — | -1886.9% | — |
| Net margin | — | — | -1011.7% | — |
| Return on assets (ROA) | -173.0% | -86.3% | -59.1% | ▲ 27 pts |
| Return on equity (ROE) | — | -113.1% | -80.8% | ▲ 32 pts |
| Free cash flow margin | — | — | -1539.2% | — |
| Current ratio | 2.56× | 6.01× | 4.34× | ▼ 28% |
Price history is added with the daily price update and will appear after the next one.